PALO ALTO, Calif., Feb. 15, 2011 /PRNewswire/ — Nfocus
Neuromedical, Inc., an innovative medical device company with a
focus on the next generation treatment for brain aneurysms,
announced today that its Luna™ Aneurysm Embolization System
(AES) received CE Mark for the treatment of patients with brain
aneurysms. The Luna AES is designed to be a
single-deployment, easy-to-use system for the treatment of brain
aneurysms both pre- and post-rupture.
“Brain aneurysm treatment historically has been the domain of
either surgery or, more recently, catheter-placed wire coils,” said
Eric Milledge, CEO, Nfocus Neuromedical. “Surgery can be
traumatic and expensive, and coils may fail to fully treat an
aneurysm. The Luna AES represents a dramatic step forward in
the treatment of these patients.”
It is estimated that up to one in 15 people will develop a brain
aneurysm during their lifetime.(1) Rupture of an aneurysm can
cause stroke, brain damage and even death.
The Luna AES treats brain aneurysms by blocking (embolizing)
blood flow while providing a scaffold to encourage tissue growth
across an aneurysm opening and create a plug. The Luna uses a
self-expandable, multi-layer oval implant made from Nitinol, a
nickel-titanium alloy. The properties of the device allow it to
easily compress within a conventional catheter, and then rapidly
and easily open to full size once deployed within an aneurysm.
“CE Mark approval is an important milestone for Nfocus,” said
Robert O’Holla, vice president of regulatory affairs, Nfocus
Neuromedical. “The Luna AES is our flagship product and we
look forward to working with physicians and hospitals in Europe to
advance this important new technology.”
About Nfocus Neuromedical, Inc.
Nfocus is developing the next generation treatment for brain aneurysms. The
company’s innovative
SOURCE
